ARF1 and prostate carcinoma: Our data demonstrate that GA-localized ARF1 inhibitors and ARF1 depletion by siRNA and CRISPR–Cas9 remarkably suppress prostate cancer cell migration and invasion induced by activation of CXCR4, an important GPCR involved in prostate cancer metastasis (46, 47).